HomeCompareMTLZF vs ABBV

MTLZF vs ABBV: Dividend Comparison 2026

MTLZF yields 1.56% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $83.8K in total portfolio value
10 years
MTLZF
MTLZF
● Live price
1.56%
Share price
$1,525.80
Annual div
$23.80
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.9K
Annual income
$0.15
Full MTLZF calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — MTLZF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTLZFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTLZF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTLZF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTLZF
Annual income on $10K today (after 15% tax)
$132.61/yr
After 10yr DRIP, annual income (after tax)
$0.13/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $21,525.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTLZF + ABBV for your $10,000?

MTLZF: 50%ABBV: 50%
100% ABBV50/50100% MTLZF
Portfolio after 10yr
$61.8K
Annual income
$12,662.47/yr
Blended yield
20.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MTLZF
No analyst data
Altman Z
3.0
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTLZF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTLZFABBV
Forward yield1.56%3.09%
Annual dividend / share$23.80$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$19.9K$103.7K
Annual income after 10y$0.15$25,324.79
Total dividends collected$157.00$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MTLZF vs ABBV ($10,000, DRIP)

YearMTLZF PortfolioMTLZF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,778$78.01$11,555$434.96$777.00ABBV
2$11,572$39.29$13,485$635.47$1.9KABBV
3$12,401$19.71$15,933$937.67$3.5KABBV
4$13,279$9.87$19,118$1,400.80$5.8KABBV
5$14,214$4.94$23,384$2,125.24$9.2KABBV
6$15,211$2.47$29,290$3,286.81$14.1KABBV
7$16,277$1.24$37,776$5,205.38$21.5KABBV
8$17,417$0.62$50,495$8,488.44$33.1KABBV
9$18,637$0.31$70,497$14,346.44$51.9KABBV
10$19,942$0.15$103,718$25,324.79$83.8KABBV

MTLZF vs ABBV: Complete Analysis 2026

MTLZFStock

Metall Zug AG, through its subsidiaries, engages in the wire processing, medical devices, infection control, technologycluster and infrastructure, and other businesses in Switzerland, rest of Europe, the Americas, the Asia Pacific, and internationally. The company's Wire Processing business unit develops, produces, and distributes semiautomatic and fully automatic machines for cutting and stripping, crimping, sealing, twisting, tinning, printing, quality control, and process and test automation for various wires and cables. This segment also offers software packages for optimizing machine efficiency and utilization for complex applications and connection of data. Its Medical Devices business unit develops, produces, and distributes diagnosis and microsurgery products primarily in the fields of ophthalmology, as well as covers applications in the fields of pulmonology and measuring instruments. This business unit offers diagnostics products, including slit lamps, biometry, perimetry, tonometer, and practice management software for clinics and opticians, as well as practice equipment; and surgical products, such as microscopes, floor and roof stands, and accessories. The company's Infection Control business unit provides cleaning, disinfection, and sterilization solutions that are used in hospitals. Its Technologycluster & Infrastructure business unit engages in the management and development of real estate. The company's Others business unit offers cleaning, disinfection and sterilization systems and solutions primarily for use in the pharmaceutical industry; and professional appliances and integrated solutions, such as dishwasher and cooking technology, cleaning agents, and care systems for the hotel and catering industry, care homes, and hospitals. Metall Zug AG was founded in 1887 and is headquartered in Zug, Switzerland.

Full MTLZF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MTLZF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTLZF vs SCHDMTLZF vs JEPIMTLZF vs OMTLZF vs KOMTLZF vs MAINMTLZF vs JNJMTLZF vs MRKMTLZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.